immatics

PRESS RELEASE

-/ ACTIVE AGAINST CANCER

immatics obtains important U.S. and European patents

Tuebingen, July 14, 2008 – *immatics biotechnologies* GmbH today announced that the company has obtained European patent protection for its technology platform XPRESIDENT™. In addition, the company has been granted important U.S. and European patents covering compounds contained in its lead product candidates IMA901 and IMA910.

"We are very pleased about the patents as they add to our growing IP portfolio in the field of peptide-based therapeutic vaccines and related compositions and technologies," said Dr Niels Emmerich, Chief Operating Officer of *immatics*. "Most importantly, our XPRESIDENT™ core technology which is the engine for all our current and future products is now protected by an issued patent. Furthermore, the granting of patents for important peptides discovered through our XPRESIDENT™ technology platform confirms our IP strategy"

Recently, the EPO has granted patent protection of *immatics'* XPRESIDENT™ drug discovery platform for the identification, selection and validation of novel tumor-associated peptides (TUMAPs). XPRESIDENT™ is a unique platform combining mass spectrometry, genomics, biochemistry, and immunology. Unlike other technologies, it is able to identify tumor-associated peptides (TUMAPs) directly from primary human tumor material, so that all TUMAPs are confirmed to be naturally processed and presented on real tumors.

XPRESIDENT™ also enables the detection of TUMAPs down to the femtomolar level – a sensitivity so far unrivaled. XPRESIDENT™ is able to identify several thousand TUMAPs per year and selects the most immunogenic antigens through a proprietary T cell validation platform. The platform can be applied to many different types of cancer.

Due to its sensitivity, XPRESIDENT™ is a very efficient discovery engine with an unprecedented and fast output of validated candidates for further clinical development.

The U.S. Patent and Trademark Office recently decided to grant a patent covering a TUMAP contained in *immatics*' drug candidates IMA901 and IMA910. Also, the

European Patent Office (EPO) issued a patent covering an additional peptide contained in IMA910. The patents cover composition of matter as well as medical use. IMA901 and IMA910, two peptide-based synthetic therapeutic vaccines for the treatment of renal cell cancer and colorectal cancer, respectively, are *immatics'* clinical-stage drug candidates.

About IMA901 and IMA910

IMA901 and IMA910 are off-the-shelf cancer vaccines consisting of multiple fully synthetic tumor-associated peptides (TUMAPs), representing tumor antigens relevant for renal cell carcinoma and colorectal cancer, respectively. IMA901 is currently developed in a European multi-center Phase II clinical trial since 2007, while IMA910 entered into a European multi-center Phase I/II clinical trial in 2008. For both products, the TUMAPs were identified based on the analysis of primary tumor tissue and have been chosen due to their ability to activate cytotoxic T cells and T helper cells against cancer.

About *immatics*

immatics biotechnologies is an independent biopharmaceutical company dedicated to the development of active immunotherapies against cancer. *immatics*' therapeutic vaccines are based on multiple tumor-associated peptides (TUMAPs) which specifically stimulate the immune system against cancer cells. Since its foundation in 2000, *immatics* has raised more than €54 million (US$ 73 million) in private equity in two financing rounds. The company has a headcount of more than 60 people and is based in Tuebingen and Munich, Germany.

For additional information please visit www.immatics.com or contact:

Dr Harpreet Singh
immatics biotechnologies GmbH
Phone: +49-7071-565125-10
E-mail: media@immatics.com